Bit Na Yang

Title: Innovations of Bit Na Yang in Cancer Treatment

Introduction

Bit Na Yang is a prominent inventor based in Gyeongsangbuk-do, South Korea. She has made significant contributions to the field of cancer treatment through her innovative research and inventions. Her work focuses on developing advanced therapeutic methods that enhance the efficacy of cancer treatments while minimizing toxicity.

Latest Patents

Bit Na Yang holds a patent for a groundbreaking invention titled "CTLA-4-targeting trans-splicing ribozyme for delivery of chimeric antigen receptor, and use thereof." This invention relates to a recombinant vector that includes a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)-targeting trans-splicing ribozyme expression cassette. The expression cassette is designed for the delivery of a chimeric antigen receptor, which is crucial for improving cancer treatment outcomes. The invention also encompasses a transformed cell, a ribozyme expressed from the recombinant vector, a retrovirus expressing the ribozyme, and a T cell treated with the retrovirus. Furthermore, it includes a pharmaceutical composition for preventing or treating cancers, which can significantly enhance therapeutic efficacy and safety.

Career Highlights

Bit Na Yang is affiliated with the Industry-Academic Cooperation Foundation at Dankook University. Her role in this institution allows her to collaborate with other researchers and contribute to the advancement of cancer therapies. Her innovative approach to gene-cell therapy aims to inhibit CTLA-4 on T cells, which has been a significant barrier in conventional anti-cancer therapies.

Collaborations

Bit Na Yang has worked alongside notable colleagues, including Seung Ryul Han and Seong Wook Lee. Their collaborative efforts have furthered the development of effective cancer treatment strategies.

Conclusion

Bit Na Yang's contributions to cancer treatment through her innovative patent demonstrate her commitment to advancing medical science. Her work not only addresses critical challenges in cancer therapy but also paves the way for future advancements in gene therapy.